Oral anticoagulants reduce events in intermediate‑risk atrial fibrillation patients, trial shows

The SINGLE‑AF trial, presented in a Hot Line session at the 2026 European Society of Cardiology Congress and published concurrently in the *New England Journal of Medicine*, found that oral anticoagulant therapy significantly reduced the risk of adverse clinical events in patients with atrial fibrillation who are classified as having intermediate stroke risk. The study enrolled a large, diverse cohort of patients and compared outcomes between those who received standard anticoagulation and those who did not receive any anticoagulant treatment.

Key findings indicate that patients on oral anticoagulants experienced fewer strokes, systemic embolic events, and major bleeding complications relative to the untreated group. The trial’s methodology included rigorous randomization, a robust follow‑up period, and comprehensive adjudication of clinical endpoints, providing strong evidence that anticoagulation benefits outweigh potential risks in this intermediate‑risk population. These results reinforce current guideline recommendations that advocate for anticoagulation in patients whose CHA₂DS₂‑VASc scores place them at intermediate risk.

In conclusion, the SINGLE‑AF trial adds compelling data to the growing body of evidence supporting the use of oral anticoagulants in intermediate‑risk atrial fibrillation patients. Clinicians can now approach treatment decisions with greater confidence that anticoagulation offers a net clinical advantage in this patient group.